Tumor Necrosis Factor Receptor Superfamily Member 9 - Pipeline Review, H2 2019
Tumor Necrosis Factor Receptor Superfamily Member 9 - Pipeline Review, H2 2019
SUMMARY
Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) pipeline Target constitutes close to 55 molecules. Out of which approximately 51 molecules are developed by companies and remaining by the universities/institutes. The latest report Tumor Necrosis Factor Receptor Superfamily Member 9 - Pipeline Review, H2 2019, outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD137 is a member of the tumor necrosis factor (TNF) receptor family. CD137 is expressed by activated T cells (but to a larger extent on CD8 than on CD4 T cells). CD137 are involved in the regulation of a wide range of immune activities. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 4, 12, 26 and 7 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 1 and 2 molecules, respectively.
Report covers products from therapy areas Oncology which include indications Solid Tumor, Colorectal Cancer, Non-Small Cell Lung Cancer, Diffuse Large B-Cell Lymphoma, Gastric Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Melanoma, Bladder Cancer, Colon Carcinoma, Follicular Lymphoma, Hematological Tumor, Lung Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Non-Hodgkin Lymphoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), B-Cell Non-Hodgkin Lymphoma, Cervical Cancer, Colon Cancer, Endometrial Cancer, Leukemia, Mantle Cell Lymphoma, Metastatic Cancer, Ovarian Cancer, Prostate Cancer, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Adenocarcinoma Of The Gastroesophageal Junction, Advanced Malignancy, Anal Cancer, B-Cell Chronic Lymphocytic Leukemia, Breast Cancer, Burkitt Lymphoma, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Esophageal Cancer, Gastroesophageal (GE) Junction Carcinomas, Gliosarcoma, Gynecological Cancer, Hepatocellular Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Kidney Cancer (Renal Cell Cancer), Lymphoma, Malignant Mesothelioma, Metastatic Lung Cancer, Multiple Myeloma (Kahler Disease), Nasopharyngeal Cancer, Pancreatic Cancer, Primary CNS Lymphoma, Primary Mediastinal B-Cell Lymphoma, Recurrent Glioblastoma Multiforme (GBM), Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Acute Myeloid Leukemia, Relapsed Chronic Lymphocytic Leukemia (CLL), Renal Cell Carcinoma, Secondary CNS Lymphoma, Squamous Cell Carcinoma, Transitional Cell Cancer (Urothelial Cell Cancer) and Triple-Negative Breast Cancer (TNBC).
Furthermore, this report also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
SUMMARY
Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) pipeline Target constitutes close to 55 molecules. Out of which approximately 51 molecules are developed by companies and remaining by the universities/institutes. The latest report Tumor Necrosis Factor Receptor Superfamily Member 9 - Pipeline Review, H2 2019, outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD137 is a member of the tumor necrosis factor (TNF) receptor family. CD137 is expressed by activated T cells (but to a larger extent on CD8 than on CD4 T cells). CD137 are involved in the regulation of a wide range of immune activities. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 4, 12, 26 and 7 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 1 and 2 molecules, respectively.
Report covers products from therapy areas Oncology which include indications Solid Tumor, Colorectal Cancer, Non-Small Cell Lung Cancer, Diffuse Large B-Cell Lymphoma, Gastric Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Melanoma, Bladder Cancer, Colon Carcinoma, Follicular Lymphoma, Hematological Tumor, Lung Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Non-Hodgkin Lymphoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), B-Cell Non-Hodgkin Lymphoma, Cervical Cancer, Colon Cancer, Endometrial Cancer, Leukemia, Mantle Cell Lymphoma, Metastatic Cancer, Ovarian Cancer, Prostate Cancer, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Adenocarcinoma Of The Gastroesophageal Junction, Advanced Malignancy, Anal Cancer, B-Cell Chronic Lymphocytic Leukemia, Breast Cancer, Burkitt Lymphoma, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Esophageal Cancer, Gastroesophageal (GE) Junction Carcinomas, Gliosarcoma, Gynecological Cancer, Hepatocellular Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Kidney Cancer (Renal Cell Cancer), Lymphoma, Malignant Mesothelioma, Metastatic Lung Cancer, Multiple Myeloma (Kahler Disease), Nasopharyngeal Cancer, Pancreatic Cancer, Primary CNS Lymphoma, Primary Mediastinal B-Cell Lymphoma, Recurrent Glioblastoma Multiforme (GBM), Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Acute Myeloid Leukemia, Relapsed Chronic Lymphocytic Leukemia (CLL), Renal Cell Carcinoma, Secondary CNS Lymphoma, Squamous Cell Carcinoma, Transitional Cell Cancer (Urothelial Cell Cancer) and Triple-Negative Breast Cancer (TNBC).
Furthermore, this report also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9)
- The report reviews Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Overview
Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Companies Involved in Therapeutics Development
AbClon Inc
ABL Bio Inc
Adagene (Suzhou) Ltd
Agenus Inc
Alligator Bioscience AB
Apogenix AG
Aptevo Therapeutics Inc
Avacta Life Sciences Ltd
Bicycle Therapeutics Plc
BioNTech SE
Bristol-Myers Squibb Co
Clover Biopharmaceuticals
Compass Therapeutics LLC
Crescendo Biologics Ltd
Eutilex Co Ltd
F. Hoffmann-La Roche Ltd
FasCure Therapeutics LLC
Hutchison MediPharma Ltd
I-Mab Biopharma Co Ltd
Inhibrx Inc
Juno Therapeutics Inc
KAHR medical Ltd
LeadArtis SL
Leads Biolabs Inc
Lyvgen Biopharma Ltd
MacroGenics Inc
Merus NV
Molecular Partners AG
Numab Innovation AG
Pfizer Inc
Pieris Pharmaceuticals Inc
Rubius Therapeutics Inc
Torque Therapeutics Inc
Xcella Biosciences Inc
Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Drug Profiles
ABL-501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ABL-503 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ADG-106 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Appendix
Global Markets Direct Report Coverage
Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Overview
Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Companies Involved in Therapeutics Development
AbClon Inc
ABL Bio Inc
Adagene (Suzhou) Ltd
Agenus Inc
Alligator Bioscience AB
Apogenix AG
Aptevo Therapeutics Inc
Avacta Life Sciences Ltd
Bicycle Therapeutics Plc
BioNTech SE
Bristol-Myers Squibb Co
Clover Biopharmaceuticals
Compass Therapeutics LLC
Crescendo Biologics Ltd
Eutilex Co Ltd
F. Hoffmann-La Roche Ltd
FasCure Therapeutics LLC
Hutchison MediPharma Ltd
I-Mab Biopharma Co Ltd
Inhibrx Inc
Juno Therapeutics Inc
KAHR medical Ltd
LeadArtis SL
Leads Biolabs Inc
Lyvgen Biopharma Ltd
MacroGenics Inc
Merus NV
Molecular Partners AG
Numab Innovation AG
Pfizer Inc
Pieris Pharmaceuticals Inc
Rubius Therapeutics Inc
Torque Therapeutics Inc
Xcella Biosciences Inc
Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Drug Profiles
ABL-501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ABL-503 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ADG-106 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Appendix
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1)
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Products under Development by Companies, H2 2019 (Contd..8), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by AbClon Inc, H2 2019
Pipeline by ABL Bio Inc, H2 2019
Pipeline by Adagene (Suzhou) Ltd, H2 2019
Pipeline by Agenus Inc, H2 2019
Pipeline by Alligator Bioscience AB, H2 2019
Pipeline by Apogenix AG, H2 2019
Pipeline by Aptevo Therapeutics Inc, H2 2019
Pipeline by Avacta Life Sciences Ltd, H2 2019
Pipeline by Bicycle Therapeutics Plc, H2 2019
Pipeline by BioNTech SE, H2 2019
Pipeline by Bristol-Myers Squibb Co, H2 2019
Pipeline by Clover Biopharmaceuticals, H2 2019
Pipeline by Compass Therapeutics LLC, H2 2019
Pipeline by Crescendo Biologics Ltd, H2 2019
Pipeline by Eutilex Co Ltd, H2 2019
Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
Pipeline by FasCure Therapeutics LLC, H2 2019
Pipeline by Hutchison MediPharma Ltd, H2 2019
Pipeline by I-Mab Biopharma Co Ltd, H2 2019
Pipeline by Inhibrx Inc, H2 2019
Pipeline by Juno Therapeutics Inc, H2 2019
Pipeline by KAHR medical Ltd, H2 2019
Pipeline by LeadArtis SL, H2 2019
Pipeline by Leads Biolabs Inc, H2 2019
Pipeline by Lyvgen Biopharma Ltd, H2 2019
Pipeline by MacroGenics Inc, H2 2019
Pipeline by Merus NV, H2 2019
Pipeline by Molecular Partners AG, H2 2019
Pipeline by Numab Innovation AG, H2 2019
Pipeline by Pfizer Inc, H2 2019
Pipeline by Pieris Pharmaceuticals Inc, H2 2019
Pipeline by Rubius Therapeutics Inc, H2 2019
Pipeline by Torque Therapeutics Inc, H2 2019
Pipeline by Xcella Biosciences Inc, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1)
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Products under Development by Companies, H2 2019 (Contd..8), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by AbClon Inc, H2 2019
Pipeline by ABL Bio Inc, H2 2019
Pipeline by Adagene (Suzhou) Ltd, H2 2019
Pipeline by Agenus Inc, H2 2019
Pipeline by Alligator Bioscience AB, H2 2019
Pipeline by Apogenix AG, H2 2019
Pipeline by Aptevo Therapeutics Inc, H2 2019
Pipeline by Avacta Life Sciences Ltd, H2 2019
Pipeline by Bicycle Therapeutics Plc, H2 2019
Pipeline by BioNTech SE, H2 2019
Pipeline by Bristol-Myers Squibb Co, H2 2019
Pipeline by Clover Biopharmaceuticals, H2 2019
Pipeline by Compass Therapeutics LLC, H2 2019
Pipeline by Crescendo Biologics Ltd, H2 2019
Pipeline by Eutilex Co Ltd, H2 2019
Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
Pipeline by FasCure Therapeutics LLC, H2 2019
Pipeline by Hutchison MediPharma Ltd, H2 2019
Pipeline by I-Mab Biopharma Co Ltd, H2 2019
Pipeline by Inhibrx Inc, H2 2019
Pipeline by Juno Therapeutics Inc, H2 2019
Pipeline by KAHR medical Ltd, H2 2019
Pipeline by LeadArtis SL, H2 2019
Pipeline by Leads Biolabs Inc, H2 2019
Pipeline by Lyvgen Biopharma Ltd, H2 2019
Pipeline by MacroGenics Inc, H2 2019
Pipeline by Merus NV, H2 2019
Pipeline by Molecular Partners AG, H2 2019
Pipeline by Numab Innovation AG, H2 2019
Pipeline by Pfizer Inc, H2 2019
Pipeline by Pieris Pharmaceuticals Inc, H2 2019
Pipeline by Rubius Therapeutics Inc, H2 2019
Pipeline by Torque Therapeutics Inc, H2 2019
Pipeline by Xcella Biosciences Inc, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
COMPANIES MENTIONED
AbClon Inc
ABL Bio Inc
Adagene (Suzhou) Ltd
Agenus Inc
Alligator Bioscience AB
Apogenix AG
Aptevo Therapeutics Inc
Avacta Life Sciences Ltd
Bicycle Therapeutics Plc
BioNTech SE
Bristol-Myers Squibb Co
Clover Biopharmaceuticals
Compass Therapeutics LLC
Crescendo Biologics Ltd
Eutilex Co Ltd
F. Hoffmann-La Roche Ltd
FasCure Therapeutics LLC
Hutchison MediPharma Ltd
I-Mab Biopharma Co Ltd
Inhibrx Inc
Juno Therapeutics Inc
KAHR medical Ltd
LeadArtis SL
Leads Biolabs Inc
Lyvgen Biopharma Ltd
MacroGenics Inc
Merus NV
Molecular Partners AG
Numab Innovation AG
Pfizer Inc
Pieris Pharmaceuticals Inc
Rubius Therapeutics Inc
Torque Therapeutics Inc
Xcella Biosciences Inc
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
COMPANIES MENTIONED
AbClon Inc
ABL Bio Inc
Adagene (Suzhou) Ltd
Agenus Inc
Alligator Bioscience AB
Apogenix AG
Aptevo Therapeutics Inc
Avacta Life Sciences Ltd
Bicycle Therapeutics Plc
BioNTech SE
Bristol-Myers Squibb Co
Clover Biopharmaceuticals
Compass Therapeutics LLC
Crescendo Biologics Ltd
Eutilex Co Ltd
F. Hoffmann-La Roche Ltd
FasCure Therapeutics LLC
Hutchison MediPharma Ltd
I-Mab Biopharma Co Ltd
Inhibrx Inc
Juno Therapeutics Inc
KAHR medical Ltd
LeadArtis SL
Leads Biolabs Inc
Lyvgen Biopharma Ltd
MacroGenics Inc
Merus NV
Molecular Partners AG
Numab Innovation AG
Pfizer Inc
Pieris Pharmaceuticals Inc
Rubius Therapeutics Inc
Torque Therapeutics Inc
Xcella Biosciences Inc
